ABSTRACT
mjn-SERAS is an earpiece shaped as a hearing-aid device, which continuously records the electrical brain activity in two channels placed in the external auditory. It uses an artificial intelligence algorithm (AI), based system for early detection of preictal period of seizures. Sixteen patients with drug-resistant focal epilepsy and 14 control subjects were simultaneously studied with the mjn-SERAS device and a standard 24-channel EEG using the 10-20 system. Data from channels F8-T4 or F7-T3, according to the laterality of the epileptic focus was extracted from the standard EEG. We analyzed the average signal correlation (AC) between the two types of records, with and without artefact removal (filtered records [FR]), comparing inter-subject and subjects recordings (SR), as well between ictal and interictal periods in epilepsy patients.
AC was 0.90 [0.88 - 0.91] and 0.88 [0.86 - 0.90] in the FR and the whole cohort, respectively. No differences in the correlation of signals were found between controls and patients in the FR (-0.01 [-0.04;0.01], p=0.261) or the SR (-0.03 [-0.06;0.01], p=0.09). In addition, in the subset of patients with epilepsy, no differences in AC were noted between interictal activity and seizures (-0.02 [- 0.06; 0.02], p=0.352). Only AC during sleep in controls was found to be smaller compared to repose (-0.04 [-0.08;-0.01], p=0.01). No adverse events were reported. Our study supports an adequate correlation between the information recorded with both methods, providing technical support for use of the mjn-SERAS to record EEG signals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by Synaptia Health Projects
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the Regional Ethical Drug Investigational Committee of Madrid
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
